Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to
At ASCO 2024 last month, editor-in-chief Jonah Comstock caught up with Dr Andree Amelsberg, SVP of global and US medical affairs at Eisai, to chat about what the company was sharing at the